STMicroelectronics N.V. (STM): what the price assumes

In the published model solve dated 2026-Q2, anchored at $52.70, STMicroelectronics N.V. (STM) is priced for today's economics sustained for ~36.9 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/STM

Headline

FieldValue
TickerSTM
CompanySTMicroelectronics N.V.
Sector / IndustryTechnology
Current price$52.70/sh
CompositionRevenues from sale of products 98% / Revenues from sale of services 2% / Other revenues 0%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Must persist for36.9y
Multiple paid259x operating income

Solve inputs: computed at a 13.5% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~4.5 years.

Reconcile: at the x-ray's 9.3% required return this reads ~22.1 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.30σ
sustained it ~10 years at this level15%
implied end-window share25%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset5.85x1expensive
Earnings2.19x3expensive
Relative1.43x3expensive
Growth1.57x3expensive

Families that call it expensive: Asset, Earnings, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=10)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$28.721.83xyesFCF base $2.2B, growth -0% (input: historical growth), terminal g 0.5%, WACC 8.8%, 5yr projection
DCF Exit MultipleGrowth$47.141.12xyesExit EV/EBITDA: 21.0x / 23.0x / 25.0x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$22.732.32xyesP/E 48.4x (blended: static sector reference 22x + trailing (TTM) 282x), scenarios: 40.9x / 48.4x / 55.9x (bear / base = reference held flat / bull), EV/EBITDA 16x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$2.0226.09xyesBV/sh $20.06, ROE (TTM) 0.9%, ke 9.3% (excluded from median)
Two-Stage Excess ReturnAsset$1.0649.72xyes5yr excess ROE then converge to ke=9.3% (excluded from median)
Discounted Future Market CapGrowth$33.631.57xyesRev $11.8B, growth -0% (input: historical growth; tapered), Terminal P/S: 3.4x / 4.0x / 4.6x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelativeno
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$21.642.44xyesNormalized EBIT (5y avg op income, one-time charges added back) $2.80B × (1−40%) / WACC 8.8% → EPV (no growth)
Residual IncomeAsset$0.7669.34xyesBV $20.06 + 5yr PV of (ROE (TTM) 0.9% − Kₑ 9.3%) × BV; BV grows 0.6%/yr (excluded from median)
Graham NumberAsset$9.015.85xyes√(22.5 × EPS $0.18 × BVPS $20.06) — Graham's conservative floor
EV/EBITDA RelativeRelative$36.741.43xyesEBITDA $2.03B × sector EV/EBITDA 16.0x
FCF YieldEarnings$26.382.00xyesFCF $2152.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$24.042.19xyesSBC-adj FCF $1.96B (FCF $2.15B − SBC $0.19B) capitalized at Kₑ
Ben Graham FormulaEarnings$0.15351.33xyesEPS $0.18 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset$1.3638.75xyesBV $20.06 × (ROIC 0.6% / WACC 8.8%) (excluded from median)
P/Sales SectorRelative$66.380.79xyesRevenue $11.80B × sector P/S 5.0x
PEG Fair ValueRelativeno
Earnings YieldEarnings$1.9527.03xyesEPS $0.18 / required return 9.3% (Rf 4.3% + ERP 5.0%) (excluded from median)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net cash$1.6b
Net debt / NOPAT (after-tax)-20.14x (net cash)
Net debt / operating income (pre-tax)-9.06x (net cash)
Interest coverage3.2x
Share count CAGR (dilution)0.0%
Burning cashno

Bullet Takeaways

Bull Case

Semiconductor makers are peculiar things to value: the worse the trailing year, the better the forward setup often is, because inventory cycles swing demand far harder than end markets actually move. STMicroelectronics right now is the textbook case. The 2025 downturn crushed reported earnings to almost nothing, yet the business still generated about $2.2 billion of free cash flow, kept $1.6 billion of net cash on the balance sheet, and covered its interest 52 times over. A company that can absorb a cyclical collapse of that magnitude without burning cash or diluting holders (the share count has been flat for four years) is structurally healthier than its trailing income statement suggests.

The turn is now visible in the numbers rather than the narrative. First-quarter 2026 revenue climbed 23 percent year over year and beat estimates, management guided the second quarter to roughly $3.45 billion at the midpoint (about 25 percent year-over-year growth) with gross margin near 34.8 percent, book-to-bill ran above one across all end markets and regions, and distribution inventory has normalized. The company's own filing marks the inflection in its bluntest available form: "For 2026, we entered the year with a backlog higher than what we had entering 2025". Layered on top is a genuinely new demand pillar: management targets data center revenue above $500 million for full-year 2026, a market STM barely addressed a cycle ago.

What converts a cyclical bounce into a durable earnings level is the cost and capacity work happening underneath. The 20-F describes the "company-wide program announced in October 2024 to reshape our manufacturing footprint and resize our global cost base": shifting wafer output to 300mm fabs at Agrate and Crolles and 200mm silicon carbide at Catania, with annual savings targeted in the high hundreds of millions of dollars exiting 2027. In China, rather than ceding the market, ST built a dedicated joint-venture foundry "for high-volume 200mm SiC device manufacturing in China" that "will make SiC devices exclusively for us, using our proprietary SiC manufacturing process technology". And the customer list the filing names (Apple, Bosch, Continental, Denso, Mobileye, Samsung, SpaceX, Tesla among them) is the kind of design-win base that does not churn quickly. The bull case is a leaner cost base meeting a rising cycle, with the balance sheet already proven under stress.

Bear Case

The advantage that made STM a default supplier to the world's car and factory-equipment makers, broad analog and power portfolios manufactured in its own European fabs, is being chipped at from the east. The company's own 20-F concedes it "could face increased competition as a result of China's programs to promote a domestic semiconductor industry and supply chains", and China is precisely where the auto and industrial volume growth lives. ST's answer, a China-for-China joint venture that licenses its proprietary silicon carbide process into a local foundry, keeps revenue in the country but also accelerates the local ecosystem's learning curve. In power semiconductors, where ST built its silicon carbide franchise on early Tesla wins, Chinese entrants compete primarily on price, and the moat was never patents so much as manufacturing yield and scale, both of which erode with time.

The structural economics make that erosion expensive to fight. The filing is unusually direct: "Our capital needs are high compared to those competitors who do not manufacture their own products and we may need additional funding in the coming years to finance our investments". The integrated-manufacturer model means every pricing cycle lands on ST's own fixed-cost base; 2025 showed the mechanism, with gross margin down "250 basis points, mainly due to lower manufacturing efficiencies" as fabs ran under-loaded. The industry pattern is well documented in peer filings too: NXP's 10-K notes that "Investments in new capacity can result in overcapacity, which can lead to a reduction in prices and margins". ST is expanding 300mm and silicon carbide capacity into a recovery whose durability is exactly what is in question.

And the price already assumes the recovery matures into something exceptional. At $71.42, the market is paying about 5.3x revenue for a business whose revenue shrank through 2025, which works out to an assumption that ST eventually earns roughly 13.6 percent operating margins while growing revenue at the fastest pace it can self-fund for something like eighteen years. Of comparable fast-growers, only about 15 percent have sustained that kind of pace even ten years. Every family of method reads the price as above its central estimate, and the average analyst target of $63.76 sits below the market price, a street-versus-price gap that says the recovery is more than fully credited. If the cycle disappoints, or if Chinese competition compresses the silicon carbide margin structure, the multiple has no cushion under it: the earnings-power read on five-year average operating income sits at roughly a third of today's price.

Valuation

Trailing earnings are nearly useless for reading this price, and the price itself says so. GAAP earnings per share over the trailing year is $0.18, an artifact of the 2025 downturn plus restructuring and impairment charges, so today's $71.42 (July 10, 2026) has to be read against sales. At about 5.3x revenue, the price implies the business eventually earns an operating margin of roughly 13.6 percent and grows revenue near its self-funding ceiling for about eighteen years. The near-term pace is within what the company has recently delivered; the stretch is the duration. Historically, only about 15 percent of comparable fast-growers sustained that pace for even ten years.

The methods we use to triangulate all land below the price, which is itself the signal: this is a bet beyond what any standard frame supports on trailing data. The gentlest reads are the sales-based ones, with the sector price-to-sales lens landing about 12 percent below the price, and a cash-flow method that reaches within about 20 percent, but only by holding today's elevated EV/EBITDA multiple, roughly 32x, flat for five years against a sector median of 16x. The earnings-based lenses are harsher: even normalizing operating income across five years, which washes out the trough, the earnings-power read sits at roughly a third of the price. Some of that gap is honest cycle math. The 20-F attributes the margin damage to "lower manufacturing efficiencies" as fabs ran under-loaded, a reversible condition, and records that "For 2026, we entered the year with a backlog higher than what we had entering 2025", so the earnings base should rise from here. The question the price forces is not whether earnings recover but whether they recover far enough, fast enough, and stay elevated long enough to close a gap this wide.

The balance sheet is not the problem. Net cash stands at $1.6 billion, interest coverage runs 52 times, the company generated about $2.2 billion of free cash flow through the trough, and the share count has held flat over four years. The downside is not solvency; it is multiple compression on a cyclical whose price already embeds a long, uninterrupted expansion. The single most decisive variable is the slope of the margin recovery that the July 23 report begins to reveal.

Catalysts

The second-quarter report arrives before the European open on July 23, 2026, carrying guidance of roughly $3.45 billion in revenue at the midpoint (about 25 percent year-over-year growth, 11.6 percent sequential) and gross margin near 34.8 percent. The quarter is less about the revenue line, which management has effectively pre-committed, than about margin delivery and the book-to-bill commentary: the first quarter showed bookings above one across all end markets and regions with distribution inventory normalized, and a second consecutive confirmation would establish the recovery as broad rather than AI-narrow.

Two structural programs supply the medium-term milestones. The manufacturing reshaping announced in October 2024, concentrating output at the 300mm Agrate and Crolles fabs and 200mm silicon carbide at Catania, targets annual cost savings in the high hundreds of millions of dollars exiting 2027, with up to 2,800 employees leaving voluntarily over three years; 2025 absorbed $376 million of impairment, restructuring, and phase-out charges, so the savings now need to show up in gross margin as volumes return. Separately, management's target of more than $500 million of full-year 2026 data center revenue gives the AI-infrastructure story a checkable number.

Street positioning is the tension to watch: the consensus rating is a buy, but the average price target of $63.76 across 15 analysts sits below the market price after the stock's run, with recent individual targets as high as $84. Upward estimate revisions following the July print, or the lack of them, will determine whether the price grows into its multiple or waits for the fundamentals to catch up.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

company Q1 2026 results and Q2 guidance · company Q2 2026 earnings calendar; company restructuring program announcement · company Q1 2026 results and Q2 2026 guidance · Q1 2026 earnings commentary · company program details, April 2025 · StockAnalysis consensus, 15 analysts, July 2026 · company Q2 2026 earnings announcement and Q1 guidance · Q1 2026 earnings call commentary · company restructuring program disclosures, 2025 · StockAnalysis and TipRanks analyst data, July 2026

View the full interactive STM report on boothcheck